Literature DB >> 10216507

The expression of proto-oncogene c-jun in human pancreatic cancer.

G Tessari1, C Ferrara, A Poletti, A Dubrovich, A Corsini, G Del Favero, R Naccarato.   

Abstract

The proto-oncogene c-jun is involved in cellular proliferation by interfering with signals that lead to cellular differentiation. Moreover the induction of metalloproteinase gene appears to utilise the c-jun oncogene as intracellular messenger. The aims of this study were to evaluate a) the expression of c-jun oncogene in pancreatic cancer b) its relation with tumor histological features. Surgical specimens of pancreatic cancer were collected from 22 patients radically operated upon, and from 11 submitted to palliation. As a control group, 5 specimens of normal pancreas and 5 specimens of chronic pancreatitis were studied. C-jun staining was graded as follows: (-) positive cells < 10%, (+) from 10 to 30%, (+2), from 30 to 60%, (+3) from 60 to 90%. Glucagon and somatostatin staining was graded counting the positive cells of total numer of Langherans islet cells counted. c-Jun expression (low: < 30% and high: > 30%) was related to stage, architectural and cytological grading, vascular, lymph nodal, perineural invasion. Normal pancreas and chronic pancreatitis tissues appear to express the c-jun protein in less than 10% of ductal cells. The percentage of tumor cells stained for c-jun is increased as compared to the control group in 28/33 cases: in 13 (46%) it ranges from 10 to 30%; in 10 (36%) from 30 to 60% and in 5 (18%) from 60 to 90%. The frequency of high or low c-jun expression is not different in relation to the histological features of tumor. Moreover, c-jun protein is present in 40% of cells of Langherans islets in normal pancreas, chronic pancreatitis and pancreatic cancer. The Langherans islet cells stained for c-jun exhibit also a positivity for glucagon. In conclusion; a) in pancreatic cancer, the expression of c-jun is increased in tumour cells in majority of cases as compared to the control group, b) a c-jun positivity is also found in alpha cells with a pattern not different from control group, but the relation between the alpha cells and c-jun production is unknown, c) c-jun expression does not vary in relation to histological findings.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10216507

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  12 in total

Review 1.  Emerging roles of ATF2 and the dynamic AP1 network in cancer.

Authors:  Pablo Lopez-Bergami; Eric Lau; Ze'ev Ronai
Journal:  Nat Rev Cancer       Date:  2010-01       Impact factor: 60.716

2.  Therapeutic effect of c-Jun N-terminal kinase inhibition on pancreatic cancer.

Authors:  Ryota Takahashi; Yoshihiro Hirata; Kosuke Sakitani; Wachiko Nakata; Hiroto Kinoshita; Yoku Hayakawa; Hayato Nakagawa; Kei Sakamoto; Yohko Hikiba; Hideaki Ijichi; Harold L Moses; Shin Maeda; Kazuhiko Koike
Journal:  Cancer Sci       Date:  2013-01-24       Impact factor: 6.716

3.  Bile acids-mediated overexpression of MUC4 via FAK-dependent c-Jun activation in pancreatic cancer.

Authors:  Suhasini Joshi; Eric Cruz; Satyanarayana Rachagani; Sushovan Guha; Randall E Brand; Moorthy P Ponnusamy; Sushil Kumar; Surinder K Batra
Journal:  Mol Oncol       Date:  2016-04-29       Impact factor: 6.603

4.  Activation of oxidative stress-responsive signaling pathways in early splenotoxic response of aniline.

Authors:  Jianling Wang; Gangduo Wang; G A S Ansari; M Firoze Khan
Journal:  Toxicol Appl Pharmacol       Date:  2008-03-04       Impact factor: 4.219

5.  Chemopreventive properties of black raspberries in N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis: down-regulation of cyclooxygenase-2, inducible nitric oxide synthase, and c-Jun.

Authors:  Tong Chen; Hyejeong Hwang; Miranda E Rose; Ronald G Nines; Gary D Stoner
Journal:  Cancer Res       Date:  2006-03-01       Impact factor: 12.701

6.  Activator protein-1 has an essential role in pancreatic cancer cells and is regulated by a novel Akt-mediated mechanism.

Authors:  Sonyo Shin; Takayuki Asano; Yixin Yao; Ronghua Zhang; Francois-Xavier Claret; Murray Korc; Kanaga Sabapathy; David G Menter; James L Abbruzzese; Shrikanth A G Reddy
Journal:  Mol Cancer Res       Date:  2009-05-12       Impact factor: 5.852

7.  Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy.

Authors:  Matthew B Lipner; Xianlu L Peng; Chong Jin; Yi Xu; Yanzhe Gao; Michael P East; Naim U Rashid; Richard A Moffitt; Silvia G Herrera Loeza; Ashley B Morrison; Brian T Golitz; Cyrus Vaziri; Lee M Graves; Gary L Johnson; Jen Jen Yeh
Journal:  JCI Insight       Date:  2020-04-23

8.  Structure and function of human DnaJ homologue subfamily a member 1 (DNAJA1) and its relationship to pancreatic cancer.

Authors:  Jaime L Stark; Kamiya Mehla; Nina Chaika; Thomas B Acton; Rong Xiao; Pankaj K Singh; Gaetano T Montelione; Robert Powers
Journal:  Biochemistry       Date:  2014-02-19       Impact factor: 3.162

9.  Pancreatic adenocarcinoma protein-protein interaction network analysis.

Authors:  Mostafa Rezaei-Tavirani; Sina Rezaei-Tavirani; Nayebali Ahmadi; Nosratollah Naderi; Saeed Abdi
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2017

10.  An increased high-mobility group A2 expression level is associated with malignant phenotype in pancreatic exocrine tissue.

Authors:  N Abe; T Watanabe; Y Suzuki; N Matsumoto; T Masaki; T Mori; M Sugiyama; G Chiappetta; A Fusco; Y Atomi
Journal:  Br J Cancer       Date:  2003-12-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.